Sugi Predict

Sugi Predict / Compounds / SCHEMBL299986

SCHEMBL299986

SCHEMBL299986

COc1ccc2c(ccn2C(=O)OC(C)(C)C)c1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 1/20 0.38
▸ BUB1 O43683 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ PDE4B Q07343 5/20 0.36
▸ PDE4A P27815 3/20 0.36
▸ PDE4C Q08493 3/20 0.36
▸ PDE4D Q08499 3/20 0.36
▸ JAK2 O60674 1/20 0.34
▸ JAK3 P52333 1/20 0.34
▸ PTK2 Q05397 1/20 0.34
▸ BCHE P06276 1/20 0.34
▸ STS P08842 1/20 0.33
▸ PIK3CD O00329 1/20 0.33
▸ ABL1 P00519 1/20 0.33
▸ EGFR P00533 1/20 0.33
▸ HCK P08631 1/20 0.33
▸ SRC P12931 1/20 0.33
▸ KDR P35968 1/20 0.33
▸ PIK3CA P42336 1/20 0.33
▸ PIK3CB P42338 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18052948 0.86 MEN1 (0.39) L3MBTL1NOTUMKDM4E
SCHEMBL3902857 0.85 L3MBTL1 (0.40) HTR6BUB1L3MBTL1PDE4BPDE4A
SCHEMBL18052970 0.82 ALDH1A1 (0.39) KDM4E
SCHEMBL20993642 0.82 HTR6 (0.39) HTR6BUB1L3MBTL1PDE4BPDE4A
SCHEMBL18054260 0.81 NOTUM (0.50) JAK2MTNR1ANOTUMKDM4E
SCHEMBL18054225 0.81 BCHE (0.34) L3MBTL1PDE4BBCHENOTUMKDM4E
SCHEMBL20224053 0.81 MEN1 (0.36) NOTUMAKT1
SCHEMBL3903859 0.81 TRPV3 (0.40) HTR6L3MBTL1
SCHEMBL29992759 0.81 FABP4 (0.46) HTR6BUB1L3MBTL1BCHENOTUM
SCHEMBL8211914 0.81 FABP4 (0.46) HTR6BUB1L3MBTL1BCHENOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050744-A1 Quinazoline derivatives as angiogenesis inhibitors AstraZeneca AB (SE) 2009-04-22 — — EP claimed
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB 2006-01-05 — — US claimed
US-8492560-B2 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2013-07-23 — — US disclosed
US-8293902-B2 Quinazoline compounds ASTRAZENECA AB (SE) 2012-10-23 — — US disclosed
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors STOKES ELAINE S E (GB) 2012-08-02 — — US disclosed
EP-1474420-B1 QUINAZOLINE COMPOUNDS ASTRAZENECA AB (SE) 2012-03-14 — — EP disclosed
EP-2292615-A1 Quinazoline compounds AstraZeneca AB (SE) 2011-03-09 — — EP disclosed
EP-1553097-B1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE ASTRAZENECA AB (SE) 2010-09-29 — — EP disclosed
US-20090156821-A1 Quinazoline compounds ASTRAZENECA AB 2009-06-18 — — US disclosed
EP-2050744-A1 Quinazoline derivatives as angiogenesis inhibitors AstraZeneca AB (SE) 2009-04-22 — — EP disclosed
EP-1309587-B1 CINNOLINE COMPOUNDS ASTRAZENECA AB (SE) 2008-12-31 — — EP disclosed
US-6887874-B2 Cinnoline compounds ASTRAZENECA AB (SE) 2005-05-03 — — US disclosed
US-20050085465-A1 Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents ASTRAZENECA AB (SE) 2005-04-21 — — US disclosed
US-20030212055-A1 Cinnoline compounds ASTRAZENECA AB (SE) 2003-11-13 — — US disclosed
US-20030207878-A1 Chemical compounds ASTRAZENECA AB (SE) 2003-11-06 — — US disclosed
US-20030199491-A1 Quinoline derivatives having vegf inhibiting activity ASTRAZENECA AB (SE) 2003-10-23 — — US disclosed
EP-1309587-A1 CINNOLINE COMPOUNDS AstraZeneca AB (SE) 2003-05-14 — — EP disclosed
WO-2002012228-A1 CINNOLINE COMPOUNDS ASTRAZENECA AB (SE) 2002-02-14 — — WO disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 — — EP disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085465-A1 Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents VEGFA, FLT4, FLT1 HTR6 4127/4885BUB1 2781/4885L3MBTL1 4153/4885
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors VEGFA, FLT1, KDR HTR6 4069/4885BUB1 2824/4885L3MBTL1 4868/4885
US-20030199491-A1 Quinoline derivatives having vegf inhibiting activity VEGFA, FLT1, FLT4 HTR6 2996/4885BUB1 1627/4885L3MBTL1 3797/4885
US-20090156821-A1 Quinazoline compounds VEGFA, FLT4, FLT1 HTR6 2292/4885BUB1 2270/4885L3MBTL1 4359/4885
US-20030207878-A1 Chemical compounds CYP3A7, HTR3C, CNR1 HTR6 997/4885BUB1 2532/4885L3MBTL1 4318/4885
US-20030212055-A1 Cinnoline compounds VEGFA, PGF, CCR7 HTR6 2075/4885BUB1 2459/4885L3MBTL1 4225/4885
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors FLT4, NOS3, FLT1 HTR6 922/4885BUB1 2074/4885L3MBTL1 897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.